OBJECTIVE: The pharmacokinetics and tissue distribution of leptin in rats was investigated. DESIGN: A catheter was inserted in the right jugular vein of rats on the day prior to experiment. The next day, blood was sampled and then a tracer dose of radioiodinated hormone was administered via the catheter. Thereafter, small (200 m ml) samples of blood were taken at regular intervals. Two experiments were conducted over different sampling times. TCA precipitated radioactivity was counted in samples of plasma and tissues. Pharmacokinetic parameters were calculated after ®tting a bi-exponential equation describing a two-pool model of plasma leptin distribution. Selected time-point plasma samples were fractioned using size exclusion chromatography and the leptin distribution determined. RESULTS: The two pool model described the pharmacokinetics of leptin in two forms: an initial fast decaying pool (t 3.4 min) and a slower decaying pool (t1a 2 71 min) with an overall clearance rate of 6.16 mlaminakg. Size exclusion chromatography showed a persistent peak (all time-points tested) of 125 I-leptin corresponding to the plasma albumin peak. The size of the free 125 I-leptin peak became diminished or absent in later time-point plasma samples. Tissue distribution of leptin at 60 min and 180 min time-points showed that the small intestine contained the highest concentration of leptin, almost four times the level found in kidneys, liver, stomach and lungs.
Introduction
Leptin is a peptide hormone which is the product of the ob gene and is exclusively synthesised by adipocytes. 1 It has been the subject of much recent research as it may provide the key to the control of weight loss and the prevention of obesity in humans. 2 Exogenous leptin administration appears to decrease appetite and reduce body mass, not only in obaob mice, but also in their lean litter mates. 3 One of the main sites of action of leptin appears to be the hypothalamus where satiety is controlled. 4 However, the actions of leptin may not be con®ned to the CNS as peripheral tissues contain an abundance of leptin receptors. 5 ± 7 Little is known about the control of leptin levels in the circulation. As with other peptide hormones, it may be expected that proteolytic degradation, clearance by the kidneys, the rate of synthesis and the presence of binding proteins, would have important effects on the circulating levels of leptin, and thus the amount which is available to activate its receptor(s).
A recent study into the pharmacokinetics of exogenous leptin in rats, used doses 1000±4000 times its endogenous levels. 8 Thus, the biological signi®cance of that study, using such high doses, must be questioned. Therefore, in the present study, we have investigated the pharmacokinetics of plasma leptin, by administering a tracer dose of 125 I-leptin to female rates and sampling blood over a prescribed period. We have also investigated the molecular species involved in maintaining the pool of circulating leptin. Finally, we have investigated the rate of leptin as it becomes distributed through the tissues of the body.
Methods

Animals and treatments
Mature, female, Wistar rats were obtained from the Central Animal Breeding House, University of Queensland. Rats were housed in individual metabolism cages and given free access to food and water. They were allowed to adapt for seven days prior to experiments. On day 6 of the adaptation period, the right jugular vein of each rat was catheterised under ketamineaxylazine anaesthesia.
Clearance of plasma leptin
On day 7, a sample of jugular blood was taken, collected into a heparinised tube and stored on ice.
125
I-leptin (7Â10 6 c.p.m., Experiment 1, and 1.12Â10 7 c.p.m., Experiment 2) with a speci®c radioactivity of 160 mCiamg (iodinated by the method of Salacinski et al 9 ) was then injected into the jugular vein (time (t) 0 min). Jugular blood (200 ml) was then sampled from each animal at regular intervals between t 2 min and t 60 min (Experiment 1), and between t 15 min and t 180 min (Experiment 2), heparinised and stored on ice. Blood samples were centrifuged and plasma stored at 720 C. At the end of each experimental period (t 60 min, Experiment 1, and t 180 min, Experiment 2), rats were killed by cervical dislocation and the following tissues collected and frozen in liquid nitrogen: brain, liver, stomach, small intestine, caecum, kidneys, lungs, heart, skin and muscle (combined gastrocnemius, soleus and plantaris). The contents of the stomach, small intestine and caecum was cleared before the tissues were frozen. Tissues were then stored at 720 C. Urine was obtained from the bladder and processed in the same way as the plasma samples.
Total and trichloroacetic acid (TCA)-precipitable material (assumed to be representative of undegraded leptin) was counted from each plasma sample by the method of Bastian et al. 10 Pharmacokinetic parameters were determined by ®tting a bi-exponential equation describing a two pool method, C Ae 7at Be 7bt , using Genstat. 11 In this equation, C represents the TCA-precipitable radioactivity per ml at time, t; A and B correspond to the concentrations of TCA-precipitable radioactivity present in each pool at time 0; and a and b are the decay rate constants for each pool. The area under the curve (AUC) method was used to calculate total plasma clearance (Cl), using the relationship Cl doseaAUC. Volume of distribution (V c ) was calculated as V c dosea(A B).
Tissue distribution of 125 I-leptin
Weighed samples of frozen tissues were homogenised in 10% (wav) TCA, kept on ice for 1 h to precipitate proteins and centrifuged (3000 g, 20 min, 4 C). Total precipitable radioactivity was counted.
Size exclusion chromatography of plasma
Plasma samples taken at 10 and 60 min (Experiment 1) and 15 and 120 min (Experiment 2) were fractionated using Sephacryl-S-300-HR chromatography (Pharmacia, Uppsala, Sweden). The column (16Â200 mm) was packed and equilibrated in phosphate buffered saline (PBS), pH 7.3, containing sodium azide, 0.02% (wav), and 10 U heparinaml.
The¯ow rate was 0.25 mlamin and 4 min fractions were collected and counted. The eluate was continuously monitored at 280 nm. The column was regularly calibrated using the following standards: blue dextran (void volume), thyroglobulin (669 kDa), apoferritin (443 kDa), lactate dehydrogenase (140 kDa), bovine serum albumin (66 kDa), ovalbumin (45 kDa) and myoglobin (17 kDa).
Leptin assay
Total plasma leptin was assayed using a rat leptin assay kit (Linco, St Charles, MO).
Degradation of 125 I-leptin
In Experiment 1, degradation of 125 I-leptin in timecourse plasma samples was determined by the assay of total and TCA precipitable counts and by calculating the percentage of non-precipitable vs total plasma radioactivity. The change in rate of leptin degradation over the time-points sampled was described by an exponential equation.
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Results
Plasma leptin concentrations
The concentrations of plasma leptin were within the normal range for mature rats. The mean (s.e.m.) concentration for animals in Experiment 1 was 3.05 AE 0.46 ngaml and for Experiment 2 was 1.79 AE 0.47 ngaml (t 0 min samples). There was no signi®cant difference between plasma leptin concentrations in the two groups (P b 0.05, Student's t test).
Clearance of 125 I-leptin from plasma
The mean TCA-precipitable radioactivity in plasma over time for Experiment 1 is shown in Figure 1 . The disappearance of 125 I-leptin occurred in two phases; an early rapid decline, a phase; and a subsequent, markedly slower b phase. The half-life of leptin in the rapidly decaying (a) phase was only 3.4 min, while the slower decaying (b) phase represented a more stable form, having a half-life of 71 min. Calculations of AUCs indicated that the a phase (0.58 c.p.m.minanl) constituted less than one-eighth of the total circulating 125 I-leptin pool (4.68 cpm.minanl). The metabolic clearance calculated from the total AUC was 6.16 mlaminakg. The initial volume of distribution was 184.5 mlakg and indicates that 125 I-leptin was distributed throughout the peripheral extracellular space. 12 
Degradation of 125 I-leptin
The degradation of 125 I-leptin, after infusion, as assessed from the ratios of plasma total and TCAprecipitable counts (Experiment 1) is presented in I-leptin in urine at 60 min is present in the degraded form, indicating that leptin is not eliminated prior to degradation.
Size exclusion chromatography of plasma 125 I-leptin Figure 3 shows the molecular mass distribution of 125 I-leptin sampled at the indicated times in the two experiments. Each chromatogram shows representative plasma samples from an animal in each experimental group. A major peak of radioactivity occurred at 66 kDa in all chromatograms, which corresponded to the serum albumin peak. Thus, the molecular species to which 125 I-leptin is bound, has an apparent molecular radius of approximately 50 kDa. A second peak (17 kDa) occurred in each chromatogram in both experiments, at the early time-point following 125 Ileptin administration (10 or 15 min), however the magnitude of this peak varied. For each animal, the size of this peak from the latter sample (60 or 120 min) was greatly reduced or absent. Thus, the major circulating form of leptin in rats appears as a complex, forming a species of approximately 66 kDa. I-leptin was least abundant in skin, muscle, heart, caecum and, interestingly, brain.
Discussion
This is the ®rst study to report the pharmacokinetics of endogenous leptin in rats. The disappearance of 125 Ileptin from plasma ®tted a bi-exponential equation describing a two pool model. The initial rapidly decaying pool corresponds to leptin in the free form. In this form, leptin becomes rapidly distributed throughout the extracellular space. Plasma leptin is presumably degraded by proteases and is rapidly converted to forms in which it becomes associated with a slower decaying pool. The biological forms which constitute this second pool of leptin, include the hormone bound to sites in the tissues and to a carrier molecule in plasma. A further form is presumably bound to functional leptin receptors, which initiate a cascade of intra-cellular events in target tissues.
The free form of leptin is rapidly removed from plasma (t1a 2 3.4 min). Other peptide hormones which occur in the free form are also rapidly removed from plasma; for example, insulin, t1a 2 3.4±3.9 min, 13 or insulin-like growth factor-1 (IGF-1) in which the free form is cleared rapidly (t1a 2 14.9 min 10 12 min
14
). However, when IGF-1 is converted to the bound form, it is retained in the plasma for a much longer period (t1a 2 148 min 10 , 264 min 14 ). This feature is I-leptin is degraded. An exponential curve was ®tted to the plasma data and 95% con®dence intervals calculated (dashed lines) using Genstat.
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Leptin pharmacokinetics and tissue distribution RA Hill et al consistent with our value for leptin in the b phase of the bi-exponential model (t1a 2 71 min), suggesting that plasma leptin is in fact bound to a carrier, analogous to the IGF binding proteins.
Size exclusion chromatography of plasma samples provides evidence consistent with the pharmacokinetic values described by the two pool model. The existence of two major 125 I-leptin peaks (66 kDa and 17 kDa) in early time-point samples, suggests that newly secreted leptin is found in these two forms in vivo. The reduction or elimination of the 17 kDa peak for all samples from the later time-points suggests that the free form of leptin was rapidly cleared. The consistent size of the 66 kDa peak at all timepoints, suggests that in this form, the stability of plasma leptin was increased. The more persistent bound form of leptin is consistent with the pharmacokinetic values for the b phase of the two pool model. Thus, this may be the more biologically signi®cant form of leptin in plasma.
Analysis of the pattern of degradation of 125 I-leptin showed that in the free form, degradation increased rapidly to an asymptotic level between 2 and 10 min after leptin release to the plasma (Figure 2 ). Therefore, the rate of degradation remained unchanged between 10 and 60 min. This suggests that leptin became bound to tissues and its plasma carrier, and again is consistent with the pharmacokinetic values.
The half-life of the bound form of leptin is more than 20 times greater than that of the free form. This ®nding indicates that free leptin is rapidly degraded and cleared from the plasma, while the bound form remains in the circulation. Areas under the bi-exponential equation curve provide values consistent with Cumin et al 8 used recombinant leptin at three supraphysiological doses (0,25, 0.5 and 1.0 mgakg), with the lowest of these, corresponding to approximately 1000 times the level of endogenous leptin. The primary aim of their study was to determine whether the major clearance process of leptin was via the kidneys. The metabolic clearance rates found for the three doses were 5.75, 7.11 and 7.04 mlakgamin (not statistically signi®cant (NS), ANOVA). This is in close agreement with the present study (6.16 mlakgamin), indicating that clearance is saturable. However, the half-lives of the leptin pools, described using a three compartment model, were much shorter in the a (1.5, 1.2 and 1.68 min) and b (7.2, 6.0, and 7.2 min) phases (up to 30 min post leptin administration) than described in the a (3.4 min) and b (71 min) phases of the present study. It is possible that at the high leptin doses used by Cumin et al, 8 the plasma leptin-binding molecule was saturated and most of the leptin would have existed in the free, rapidly degraded form. Their data would therefore provide an inaccurate estimate of the halflife of endogenous leptin.
In a study of leptin pharmacokinetics in humans, Klein et al 16 used an arteriovenous balance method and found that the rate of clearance of plasma leptin was 1.50 mlakgamin. This lower rate of clearance may indicate that leptin in humans remains biologically active for a longer period than in rodents. However, it is likely that leptin association with carrier molecules which appear to be different across the species investigated to date, 17, 18 is an important factor affecting leptin clearance. Since plasma leptin pharmacokinetics were not resolved into more than one pool using this method, it is not possible to directly compare values such as half-life of plasma leptin. However, the value found for its half-life (25 min) is intermediate between the values found in the a (3.4 min) and b (71 min) phases in the present study.
We have partially elucidated the fate of circulating leptin, by examining the tissue distribution of bound leptin 60 min and 180 min following intravenous tracer administration. The most obvious feature of the tissue distribution of 125 I-leptin is the high proportion which became bound to the small intestine (Figure 4) . The high abundance of 125 I-leptin in the peripheral tissues compared to brain is consistent with data from studies of leptin receptor (ObR) m-RNA expression in both rodents and humans. 5 ± 7,19,20 Using Northern blot analysis, 5 mouse tissues with the highest abundance of ObR-RNA appeared to be lung and kidney, with less in the heart, liver, spleen, muscle and brain, and absent from the testis. The distribution of tissue expression may be quite species-speci®c, as in human tissues the highest expression was found in the heart, liver, small intestine, prostate and ovary, whereas levels were relatively lower in the lung and kidney. The most enlightening study of this kind was reported by Ghilardi et al, 6 who quanti®ed the results of RNase protection assays using densitometry. In normal mouse tissues, m-RNA from both the long and the short isoforms of the receptor were detected, and the abundance of the long isoform expressed as a percentage of the total Ob-R m-RNA. Interestingly, stomach (11%), small intestine (7%), pancreas (11%), skeletal muscle (8%) and heart (10%) had comparable abundance to that in the brain (18%), however the level in the hypothalamus was higher (36%).
Our ®ndings, together with this evidence and the apparent multiple effects of leptin action, 21 have led us to begin the formulation of a hypothesis about a possible signalling role for leptin in peripheral tissues. It seems likely, based on previous studies, that the long isoform of the Ob-R is the only form involved in intracellular signalling (reviewed in Tartaglia 22 ), thus its occurrence and role in peripheral tissues must be considered.
Of note, is the existence of a nucleotide sequence, which predicts a soluble receptor (Lee et al . The predicted molecular radius of this isoform of the receptor (Ob-R e ) when bound to leptin is of the order of 100 kDa. This molecular radius is in excess of that which we have shown, using size exclusion chromatography, represents a major peak of 125 I-leptin in plasma (66 kDa). This suggests that the major peak may be leptin bound to another carrier molecule. It is possible that Ob-R e undergoes limited proteolytic degradation, resulting in a species with a molecular radius of the order of 50 kDa. In agreement with our ®ndings, Houseknecht et al 17 have shown that in normal mice with low circulating leptin levels, the majority of the hormone exists in the bound form. They elucidated the molecular radius of the binding molecules using SDS-PAGE, followed by immunoblotting or radioligand blotting. Thus, these species Leptin pharmacokinetics and tissue distribution RA Hill et al were denatured and either resolved in reducing or nonreducing conditions prior to blotting. The effect of this treatment may have caused a difference between the molecular radius of the binding species found in their study (240, 176 and 85 kDa) when compared to our results. Alternatively, mouse and rat binding molecules may be quite different. Sinha et al 18 have also found a number of molecules in human serum which bind 125 I-leptin in ligand blots. Species with molecular radii of 280, 130, 100, 80, 75 and 68 kDa were resolved. Thus, there appear to be species differences in leptin-binding molecule pro®les.
Conclusion
We have found that the pharmacokinetics of plasma leptin in rats is affected by three important factors.
Firstly, leptin appears to bind to a carrier molecule, a factor which increases its half-life in plasma and presumably protects it from proteolytic degradation and clearance through the kidneys. Secondly, leptin becomes associated with abundant sites in peripheral tissues, a factor which, may not only protect it from proteolytic degradation, but also provides an additional pool of leptin. The role of these sites with regard to direct metabolic effects remains uncharacterised. Finally, the biological signi®cance of the rate of synthesis of leptin may be less important than originally believed as the prolonged half-life of leptin in plasma and the additional pool of tissue binding sites are important factors in determining its plasma concentration, and presumably the concentration which is required to elicit a response in the target tissues.
